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Abstract 
Background: Isolation of non-tuberculous mycobacteria (NTM) from the sputum of patients 
with cystic fibrosis (CF) is challenging due to the overgrowth of rapidly-growing species that 
colonise the lungs of patients with CF. Extended incubation of Burkholderia cepacia  
selective agar (BCSA) has been recommended as an expedient culture method for isolation of 
rapidly-growing NTM in this setting.  
Methods: Five commercially available pre-poured media for the isolation of Burkholderia 
cepacia complex (BCC) were assessed and compared with two media designed specifically 
for the isolation of mycobacteria (RGM medium and Middlebrook 7H11 selective agar). All 
seven media were challenged with 147 isolates of rapidly-growing mycobacteria, 43 isolates 
of BCC and 142 isolates belonging to other species. RGM medium was then compared with 
the most selective brand of BCSA for the isolation of NTM from 216 sputum samples from 
patients with CF.  
Results: RGM medium supported the growth of all isolates of mycobacteria and was more 
selective against other bacteria and fungi than any other culture medium. NTM were 
recovered from 17 sputum samples using RGM medium compared with seven samples using 
the most selective brand of BCSA (P = 0.023). 
Conclusions: RGM medium offers a superior option than any of the other selective agars for 
isolation of rapidly-growing mycobacteria from the sputum of patients with CF. Furthermore, 
the convenience of using RGM medium enables screening for rapidly-growing NTM in all 
sputum samples submitted by patients with CF. 
 
 
 
Introduction 
Burkholderia cepacia complex (BCC) and non-tuberculous mycobacteria (NTM) are both 
recognized as potentially important pathogens when isolated from the lungs of patients with 
cystic fibrosis (CF). The use of a selective culture medium specifically designed for the 
isolation of BCC from the sputum of cystic fibrosis patients is recommended [1] and several 
brands of such media are commercially available. 
Rapidly-growing mycobacteria (RGM) represent a subset of NTM that generate colonies on 
solid culture media within seven days of incubation [2]. The predominant species of NTM 
within the CF population in Europe is Mycobacterium abscessus complex (MABSC) [3-5] 
and there is convincing evidence that the prevalence of infection by MABSC is increasing in 
the CF population [3,5-7]. This rapidly-growing species comprises three subspecies: 
Mycobacterium abscessus subsp. abscessus, Mycobacterium abscessus subsp. bolletii and 
Mycobacterium  abscessus subsp. massiliense.  
Culture of mycobacteria from sputum samples relies upon traditional methods that were 
designed to accommodate slow growing mycobacteria – in particular Mycobacterium 
tuberculosis, which is comparatively rare in cystic fibrosis patients. Such methods are 
laborious and expensive as they involve chemical decontamination of samples and 
subsequent culture on both liquid and solid media [8,9]. Furthermore, contamination of 
cultures by faster-growing microorganisms may mean that cultures have to be abandoned [9], 
and decontamination protocols may reduce the yield of mycobacteria [8].  
Esther et al. (2011) demonstrated that extended incubation of BCSA afforded an increased 
recovery rate of NTM from 0.7% to 2.8% using routine culture methods and recommended 
this as an expedient method for culture of rapidly-growing species from patients with CF 
[10]. The aim of this study was to assess five commercially-available media for the isolation 
of BCC for their ability to support the growth of BCC (n = 43) and rapidly growing 
mycobacteria (n = 147). We also assessed the selectivity of these culture media against 142 
other bacteria and fungi with a bias towards the inclusion of species frequently recovered 
from the sputum of patients with CF. Two agar-based media designed for the isolation of 
mycobacteria (RGM medium and Middlebrook selective agar) were included for comparison. 
The two media with the most potential to recover mycobacteria were compared for their 
ability to isolate NTM from sputum samples from patients with CF. 
Materials and methods 
Materials 
All five media for isolation of BCC were purchased as pre-poured plates from their respective 
manufacturers. Burkholderia cepacia  selective agar (BCSA; Product Ref: 33631) and 
Cepacia selective agar (Product Ref: 44347) were purchased from bioMérieux, Basingstoke, 
UK or bioMérieux, Nürtingen, Germany. Burkholderia cepacia  agar (Product Ref: PO0938) 
was purchased from Oxoid Ltd, Basingstoke, UK. BD Cepacia medium (Product Ref: 
256180) and BD OFPBL (oxidation-fermentation polymyxin-bacitracin-lactose) medium 
(Product Ref: 254481) were purchased from BD Diagnostic Systems, Oxford, UK. 
Middlebrook 7H11 agar (Product Ref: PP4080) was obtained from E&O Laboratories, 
Bonnybridge, UK and RGM medium was prepared in house as previously described [11]. 
Blood agar was prepared from Columbia agar powder (Oxoid, Basingstoke, UK) and 
supplemented with 5% defibrinated horse blood (TSC Biosciences, Buckingham, UK). 
Sabouraud agar was prepared from Sabouraud dextrose agar powder (Product Ref: CM0041), 
provided by Oxoid, Basingstoke, UK.   
 
 
 
Bacterial strains 
A collection of 147 isolates of rapidly-growing mycobacteria previously isolated by standard 
methods from sputum samples from patients with CF was used for evaluation of all media. 
These included Mycobacterium abscessus subsp. abscessus (n = 79), Myobacterium chelonae 
(n = 43), Mycobacterium abscessus subsp. massiliense (n = 12), Mycobacterium abscessus 
subsp. bolletii (n = 3), Mycobacterium fortuitum (n = 3), Mycobacterium salmoniphilum (n = 
3), Mycobacterium llatzerense (n = 2), Mycobacterium immunogenum (n = 1) and 
Mycobacterium mucogenicum (n = 1). Seventy three of these isolates were obtained from the 
Microbiology Department, Freeman Hospital, Newcastle upon Tyne, UK and all were from 
distinct patients. Seventeen were kindly provided by St. Vincent's University Hospital, 
Dublin, Ireland and were also from distinct patients. The remaining 57 were consecutive 
clinical isolates kindly supplied by Public Health England, Newcastle upon Tyne, UK. The 
species and subspecies identity of all strains had been previously confirmed by sequencing of 
at least two of three housekeeping genes (rpoB, hsp65 and sodA) as previously described 
[12]. 
 
The collection of non-mycobacteria was selected to represent a variety of species frequently 
recovered from the sputa of patients with CF. Non-mycobacterial strains (n = 185) were 
obtained from national culture collections (n = 23) or from the culture collection of the 
Microbiology Department, Freeman Hospital, Newcastle upon Tyne (n = 162) and included 
an international Pseudomonas aeruginosa reference panel (n = 43) [13] and a BCC 
experimental strain panel (n = 26) [14-16] as well as clinical isolates of both species. In total, 
the collection comprised: Pseudomonas aeruginosa  (n = 55), BCC (n = 43), Staphylococcus 
aureus (n = 28), Enterobacteriaceae (n = 11), Achromobacter xylosoxidans (n = 8), Ralstonia 
mannitolilytica (n = 7), Stenotrophomonas maltophilia  (n = 4), Streptococcus spp. (n = 4), 
Aspergillus spp. (n = 3), Bacillus subtilis (n = 1), Candida spp. (n = 3), Pandoraea spp. (n = 
3), Acinetobacter spp. (n = 2), Enterococcus spp. (n = 2), Inquilinus limosus (n = 2), 
Scedosporium spp. (n = 2), Delftia acidovorans (n = 1), Elizabethkingia miricola  (n = 1), 
Geosmithia argillacea  (n = 1), Haemophilus influenzae (n = 1), Moraxella catarrhalis (n = 
1), Neisseria flavescens (n = 1) and Ochrobactrum sp. (n = 1).  
 
Inoculation of isolates onto media 
Strains were previously stored at -20oC in glycerol/skimmed milk and frozen isolates were 
subcultured onto Columbia agar with 5% horse blood prior to testing. Each isolate was 
suspended in 1 ml of saline (0.85%) to a turbidity equivalent to a McFarland 0.5 standard 
(approximately 1.5 × 108 CFU/ml) using a densitometer. For NTM rough colony-types where 
clumping occurred, vortexing with three sterile 3 mm glass beads for 10 min effectively 
dispersed all clumps. A 1 μl aliquot of each suspension of mycobacteria was inoculated onto 
each medium type and the inoculum was spread using a loop. Filamentous fungi were 
inoculated in the same way. Suspensions of all other isolates were inoculated onto media 
using a multipoint inoculator to deliver inocula of approximately 1 μl per spot (i.e. 
approximately 1.5 × 105 CFU/spot). All plates were incubated at 30°C and growth was 
recorded after four, seven days and ten days of incubation. To demonstrate the viability of 
isolates, Columbia blood agar for bacterial isolates and Sabouraud agar for fungal isolates 
were used as controls. All tests were performed in duplicate on separate occasions. 
 
Comparison of RGM medium with BCSA for isolation of mycobacteria from sputum samples. 
A total of 216 sputum samples were collected from 130 adults and children with CF attending 
the Christiane Herzog CF-Centre, University Hospital Frankfurt, Frankfurt am Main, 
Germany between July 2015 and January 2016. Samples were digested using Copan Sputum 
Liquefying solution in accordance with manufacturer’s instructions. After vortexing for 30 s 
samples were left for 15 minutes. A 100 µL aliquot was then cultured onto RGM and BCSA 
(bioMérieux Ref: 33631) and the inoculum was spread to obtain isolated colonies. Both 
media were incubated for 10 days at 30°C and examined for growth after 4, 7 and 10 days of 
incubation. A minority of samples were read after 11-12 days of incubation if the day of the 
final reading fell on a weekend. 
  
Colonies were identified using matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (VITEK-MS, bioMérieux, Nürtingen, Germany). Suspected isolates of 
mycobacteria were further confirmed as acid-fast bacilli using a Ziehl-Neelsen stain and 
identified to species level by ITS sequencing………further details (and / or reference) 
required. 
 
Statistical analysis 
Any difference in performance of the two media for isolation of NTM from sputum samples 
was investigated for statistical significance using McNemar's test with the continuity 
correction applied. Statistical significance was assigned to a probability (P) value of ≤ 0.05. 
 
Results 
 
Evaluation of seven selective agars for supporting the growth of mycobacteria . 
Clear differences were revealed between the five different brands of BCSA in terms of their 
ability to support the growth of mycobacteria. For example, on Cepacia selective agar 
(bioMérieux) 95.9% of mycobacteria generated growth within 4 days of incubation compared 
with only 40.1% of isolates on Oxoid B. cepacia agar (Table 1). After 10 days of incubation, 
ten isolates has still not grown on Oxoid B. cepacia agar including MABSC (n = 4), M. 
chelonae (n = 3), M. llatzerense (n = 2) and M. mucogenicum (n = 1). All isolates were 
recovered on Cepacia selective agar (bioMérieux; Ref: 44347) whereas other brands[S1] of 
BCSA failed to support the growth of between four and eight isolates. All isolates were 
recovered on Middlebrook 7H11 selective agar and RGM medium. 
 
 
 
Table 1: Percentage of mycobacteria recovered on various selective agars at 30°C.
BCSA Cepacia 
selective agar
B. cepacia 
agar
Cepacia 
medium OFPBL
RGM 
medium
Middlebrook 
7H11 agar
bioMérieux bioMérieux Oxoid BD BD N/A E&O Laboratories
33631 44347 PO0938 256180 254481  - PP4080
MABSC 94
Day 4 92.6 96.8 57.4 96.8 93.6 98.9 98.9
Day 7 98.9 98.9 91.5 98.9 98.9 98.9 98.9
Day 10 98.9 100 95.7 100 98.9 100 100
M. chelonae 43
Day 4 97.7 100 9.3 95.3 100 100 100
Day 7 100 100 69.8 95.3 100 100 100
Day 10 100 100 93 97.7 100 100 100
Other species 10
Day 4 10 70 10 70 40 90 70
Day 7 30 80 60 70 40 90 70
Day 10 30 100 70 70 70 100 100
Total mycobacteria 147
Day 4 88.4 95.9 40.1 94.6 91.8 98.6 97.3
Day 7 94.6 98 83 95.9 95.2 98.6 97.3
Day 10 94.6 100 93.2 97.3 97.3 100 100
n
  
 
 
Table 2: Number of non-mycobacteria isolates recovered on various selective agars 
after 10 days of incubation at 30°C.
BCSA Cepacia 
selective agar
B. cepacia 
agar
Cepacia 
medium OFPBL
RGM 
medium
Middlebrook 
7H11 agar
bioMérieux bioMérieux Oxoid BD BD N/A E&O Laboratories
33631 44347 PO0938 256180 254481  - PP4080
Gram Negatives 141 54 60 55 59 72 18 63
Enterobacteriaceae 11 2 0 2 2 6 0 1
A. xylosoxidans 8 3 3 3 5 8 2 3
Acinetobacter sp. 2 0 0 0 0 0 0 0
B. cepacia  complex 43 37 40 36 37 41 12 39
D. acidovorans 1 1 0 0 0 1 0 0
E. miricola 1 1 1 1 0 1 0 1
H. influenzae 1 0 0 0 0 0 0 0
I. limosus 2 0 2 0 2 0 1 2
M. ca ta rrha lis 1 0 0 0 0 0 0 0
Neisseria  flavescens 1 1 1 1 1 1 1 1
Ochrobactrum sp. 1 0 1 1 1 1 0 1
P. aeruginosa 55 0 2 1 2 2 0 2
Pandoraea  spp. 3 3 3 3 3 3 2 3
R. mannitolilytica 7 6 6 6 6 5 0 7
S. ma ltophilia 4 0 1 1 0 3 0 3
Gram Positives 35 3 11 3 14 21 0 7
B. subtilis 1 0 0 0 0 0 0 0
Enterococcus spp. 2 0 0 0 0 0 0 0
S. aureus 28 3 11 3 14 21 0 7
Streptococcus spp. 4 0 0 0 0 0 0 0
Yeast and Fungi 9 5 8 9 8 8 0 3
A. fumiga tus 2 2 2 2 2 2 0 0
A. terreus 1 1 1 1 1 1 0 1
Candida  spp. 3 2 3 3 3 3 0 1
G. a rgillacea 1 0 0 1 0 0 0 0
S. apiospermum 1 0 1 1 1 1 0 1
S. prolificans 1 0 1 1 1 1 0 0
Total 185 62 79 67 81 101 18 73
Total excluding     
B. cepacia 
complex
142 25 39 31 44 60 6 34
n
Evaluation of seven selective agars for inhibition of non-mycobacteria. 
Table 2 provides insights into the selectivity of the seven selective media with 185 non-
mycobacteria. All of the five brands of BCSA showed effective inhibition of P. aeruginosa , 
which is an essential attribute of such media. Inhibition of other species was more variable 
however. For example, of 28 isolates of S. aureus (mainly methicillin-resistant strains), 21 
(75%) were able to grow on BD OFPBL medium whereas only three isolates were able to 
grow on Oxoid B. cepacia agar and bioMérieux BCSA. All brands of media for isolation of 
BCC showed a poor ability to inhibit the growth of fungi – particularly Aspergillus spp. and 
yeasts. Overall, bioMérieux BCSA showed the greatest selectivity and BD OFPBL showed 
the weakest selectivity among the five brands tested.  
 
Although Middlebrook selective medium is designed specifically for the isolation of 
mycobacteria from clinical samples, the growth of other non-mycobacterial species was 
relatively common with 75 out of 186 (40.3%) isolates able to grow. Overall, its selectivity 
was inferior to the two most selective media for BCC, although it was able to inhibit the 
growth of Aspergillus fumigatus. RGM medium was by far the most selective of all of the 
agars tested, with 90% of non-mycobacteria inhibited including all fungi and Gram-positive 
bacteria. 
 
Performance of selective agars for isolation of BCC. 
Of the five brands of media for BCC, none was able to support the growth of every isolate of 
BCC within the standard incubation period of 5 days (Table 3). Cepacia selective agar 
(bioMérieux; 44347) showed the highest sensitivity (93%) with only three isolates inhibited 
(1 B. stabilis and 2 B. multivorans) whereas the growth of seven isolates was inhibited on 
Oxoid B. cepacia agar (B. cenocepacia (n = 1), B. multivorans (n = 5), B. stabilis (n = 1)). 
Extended incubation up to ten days resulted in three additional isolates recovered on BD 
OFPBL medium but had no impact on other brands of BCSA. 
 
 
 
Comparison of RGM medium with BCSA for recovery of mycobacteria from sputum samples. 
A total of 17 isolates of mycobacteria were recovered from 216 sputum samples (Table 4). 
These 17 isolates were derived from a total of 12 patients (prevalence: 12/130; 9.2%). All 17 
isolates of mycobacteria were recovered on RGM medium compared with only seven (41%) 
recovered on BCSA (P = 0.023). For seven of 12 patients, mycobacteria were only detected 
using RGM medium (P = 0.023).  The calculation of sensitivity [S2]in Table 4 is for 
comparative purposes only and assumes that all mycobacteria were recovered by at least one 
of the two methods. Clearly this cannot be proven and moreover might be considered 
unlikely for slower-growing species such as M. avium complex. The average time-to-
Table 3: No. of isolates of B. cepacia  complex recovered on various selective agars 
after 5 days of incubation at 30°C.
BCSA Cepacia 
selective agar
B. cepacia 
agar
Cepacia 
medium OFPBL
RGM 
medium
Middlebrook 
7H11 agar
bioMérieux bioMérieux Oxoid BD BD N/A E&O Laboratories
33631 44347 PO0938 256180 254481  - PP4080
B. ambifaria 2 1 2 2 2 1 0 0
B. anthina 2 1 2 2 1 1 0 1
B. cenocepacia 11 11 11 10 9 10 3 11
B. cepacia 3 3 3 3 3 3 0 3
B. contaminans 1 1 1 1 1 1 0 1
B. dolosa 2 2 2 2 2 2 0 1
B. multivorans 12 10 10 7 10 11 2 10
B. pyrrocinia 2 2 2 2 2 2 1 1
B. stabilis 4 2 3 3 3 3 0 3
B. vietnamiensis 4 4 4 4 4 4 0 4
Total 43 37 40 36 37 38 6 35
%  recovery 86 93 84 86 88 14 81
n
detection for mycobacteria was 7.9 days using RGM medium (range 4-11 days) and 7 days 
using BCSA (range 4-11 days). 
 
 
 
Table 4 shows that RGM medium was much more selective than BCSA for the inhibition of 
non-mycobacteria with only 16 isolates of non-mycobacteria recovered on RGM medium 
from 216 sputum samples (compared with 56 on BCSA). This is highly likely to have had an 
impact on the recovery of mycobacteria on BCSA. For example, for the ten sputum samples 
Table 4: Numbers of isolates of mycobacteria and other species recovered 
on BSCA and RGM medium from culture of 216 sputum samples.
RGM BCSA
Total mycobacteria 17 7
M. abscessus complex 9 6
M. avium complex 1 0
M. chelonae 1 0
M. mucogenicum 2 0
M. simiae 3 1
Mycobacterium species 1 0
Sensitivity (%) 100 41
Total non-mycobacteria 16 56
Achromobacter sp. 6 12
Burkholderia multivorans 5 6
Cryseobacterium sp. 0 1
Cupriavidus sp. 1 1
Proteus mirabilis 0 4
Pseudomonas aeruginosa 0 7
Serratia marcescens 0 2
Shingobacterium spiritivorum 0 1
Stenotrophomonas maltophilia 0 2
Aspergillus fumigatus 2 9
Aspergillus terreus 0 1
Candida sp. 1 7
Exophiala dermatitidis 0 1
Geotrichum sp. 1 1
Unidentified fungus 0 1
No growth 183 155
shown to contain mycobacteria that were not recovered on BCSA, five of these showed 
growth of other bacterial species (n = 3) or fungal species (n = 2) on BCSA. All 17 isolates of 
mycobacteria recovered on RGM medium were isolated in pure culture. 
 
[S3] 
 
Discussion 
 
The accurate and prompt detection of rapidly growing NTM for patients with CF is important 
for treatment management and for infection control purposes. In the only previously reported 
study, RGM medium was compared with Cepacia selective agar (bioMérieux; 44347) for the 
isolation of mycobacteria from 502 sputum samples. Mycobacteria were detected in 54 
samples using RGM medium and from only 17 samples using Cepacia selective agar (P ≤ 
0.0001) [12]. As media for isolation of B. cepacia  have been recommended for isolation of 
mycobacteria, this prompted us to examine different commercial brands of such media to 
Table 4: Selective agents included in various culture media as disclosed by manufacturers.*
BCSA Cepacia 
selective agar
B. cepacia 
agar
Cepacia 
medium OFPBL
RGM 
medium
Middlebrook 
7H11 agar
bioMérieux bioMérieux Oxoid BD BD N/A
E&O 
Laboratories
33631 44347 PO0938 256180 254481  - PP4080
Polmyxin B 600 000 U 300 000 U 150 000 U 300 000 U 300 000 U ND Included
Crystal violet 2 mg 1 mg 1 mg 1 mg  - ND -
Bile salts  - 0.5 g 1.5 g 0.5 g  - ND -
Ticarcil l in  - 10 mg 100 mg 100 mg  - ND Included
Gentamicin 10 mg  - 5 mg  -  - ND -
Vancomycin 2.5 mg  -  -  -  - ND -
Bacitracin  -  -  -  - 200 U ND  -
Trimethoprim  -  -  -  -  - ND Included
Amphotericin B  -  -  -  -  - ND Included
Malachite Green  -  -  -  -  - ND Included
*The composition of these media may be adjusted by manufacturers to meet performance requirements.
ND: Not disclosed. Concentrations are not published for selective agents in E&O Middlebrook agar.
compare their ability to support the growth of mycobacteria and their selectivity against other 
flora associated with CF sputum samples. Cepacia selective agar (bioMérieux; 44347) was at 
least as effective for culture of pure strains of mycobacteria as any other selective agar for B. 
cepacia. It was less selective than some other agars and much of this could be attributed to 
lack of inhibition of methicillin-resistant S. aureus. Cepacia selective agar was less selective 
than bioMérieux BSCA but more selective than BD OFPBL. 
 
In 1985, Gilligan et al. were the first to report the design of a selective culture medium for B. 
cepacia (PC medium) for use with sputum samples from patients with CF [17]. Their 
medium included polymyxin B, ticarcillin, crystal violet and bile salts as selective agents and 
such agents are commonly exploited in commercial brands. At around the same time, Welch 
et al. evaluated the use of OFPBL medium, exploiting the use of polymyxin B and bacitracin 
as selective agents [18]. Finally, in 1997, Henry et al. described B. cepacia selective agar 
(BCSA) and showed it to have greater selectivity than PC agar and OFPBL medium. In this 
medium, polymyxin B and crystal violet were retained as selective agents with the addition of 
gentamicin and vancomycin [19]. In a large trial with 656 clinical samples, Henry et al. 
concluded that BCSA was superior to OFPBL and PC medium for supporting the growth of 
B. cepacia and suppressing the growth of other flora [20]. In this study we re-affirm the high 
selectivity of BCSA, which was much more selective than OFPBL, however, six isolates of 
BCC were inhibited using BCSA. The selective agents exploited by various pre-poured 
media commercially available for isolation of BCC are detailed in Table 5.  
 
Mycobacteria grow more slowly than most if not all of the other bacterial and fungal isolates 
commonly recovered from sputum samples from patients with CF. This means that high 
selectivity is extremely important to inhibit or restrict the growth of non-mycobacteria so that 
they do not remain undetected due to overgrowth by other species. Although BCSA was the 
most selective of the agars designed for recovery of BCC, it was much less selective than 
RGM medium. If BCC is excluded (as BCSA is designed to grow this), 25 non-mycobacteria 
were able to grow on BCSA compared with only six on RGM medium (Table 1). A particular 
drawback of selective agars for BCC is their failure to inhibit fungi, and particularly 
Aspergillus species. On extended incubation of these media, the growth of Aspergillus can 
overwhelm the entire culture plate severely compromising the isolation of mycobacteria. This 
is particularly problematic with sputum samples from CF patients where infection of 
mycobacteria has been associated with concomitant isolation of Aspergillus sp. [21, 22].  
 
Middlebrook 7H11 selective agar, designed for isolation of mycobacteria, was better at 
inhibiting fungi, due to the inclusion of amphotericin (Table 5).  However, other species, such 
as Aspergillus terreus and Scedosporium apiospermum remained uninhibited and overall the 
selectivity of Middlebrook 7H11 selective agar was inferior to that of bioMérieux BCSA and 
Oxoid B. cepacia agar (Table 1). In contrast, no yeasts or fungi were able to grow on RGM 
medium.  
As a result of these findings, RGM was compared with BCSA for the isolation of 
mycobacteria from 216 sputum samples. The data confirm the superior selectivity of RGM 
medium and it is likely that this facilitated the significantly greater yield of mycobacteria 
recovered on RGM medium (P = 0.023). We believe that the use of RGM medium constitutes 
a simple, convenient method for culture of mycobacteria that can be embedded within routine 
diagnostic methods allowing the culture of all submitted sputum samples from patients with 
CF. A dedicated culture method for detection of BCC is accepted practice for sputum 
samples from patients with CF [1] and it is noteworthy that NTM were recovered in almost 
three times as many samples as BCC in this study. From our analysis we conclude that RGM 
medium offers a superior option compared with any of the other selective agars for isolation 
of rapidly-growing mycobacteria from the sputum of patients with CF. It is anticipated that 
RGM medium will be made commercially available in due course but until then, the authors 
are committed to making the culture medium freely available to clinical laboratories who 
wish to independently verify the findings of this study. Further studies are required to 
compare the sensitivity of RGM medium with formal culture methods for acid-fast bacilli 
(i.e. automated liquid culture). It would also be of interest to examine the utility of RGM 
medium in locations where slower-growing species of mycobacteria, such as M. avium 
complex, may predominate. 
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